However, IL-15-modified CAR T-cells were still susceptible to antigen escape as gliomas that recurred after 40 days following CAR T-cell treatment, suggesting that targeting multiple antigens may still be necessary in addition to providing cytokine support. The gene discussed is IL15; the disease is glioma.